Mitomycin C and 5-fluorouracil salvage chemotherapy in platinum-resistant ovarian carcinoma

P. Benedetti Panici, S. Greggi, G. Scambia, M. G. Salerno, G. Baiocchi, R. Cento, S. Mancuso

Research output: Contribution to journalArticlepeer-review


Twenty-four patients with progressing or recurrent ovarian carcinoma, all pre-treated with cisplatin, were evaluated for response and toxicity to mitomycin C (MMC) and 5-fluorouracil (5-FU) chemotherapy. Eligible patients had histologically proven intra-abdominal disease (67% clinically measurable; 33% nonmeasurable), and 67% of them had progressed on prior platinum-based chemotherapy. WHO response criteria were adopted in patients with measurable disease while those with nonmeasurable lesions were considered as responding in case of nonevident disease and CA-125 values

Original languageEnglish
Pages (from-to)183-187
Number of pages5
Issue number3
Publication statusPublished - 1992


  • 5-Fluorouracil
  • Chemotherapy
  • Mitomycin C
  • Ovarian cancer
  • Platinum-resistance
  • Salvage treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Mitomycin C and 5-fluorouracil salvage chemotherapy in platinum-resistant ovarian carcinoma'. Together they form a unique fingerprint.

Cite this